208 related articles for article (PubMed ID: 38106421)
1. Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis.
Zheng Y; Feng B; Chen J; You L
Front Immunol; 2023; 14():1273220. PubMed ID: 38106421
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis.
Wang H; Liang S; Yu Y; Han Y
Front Oncol; 2024; 14():1276549. PubMed ID: 38292925
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
Yu Z; Xu F; Zou J
Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
[TBL] [Abstract][Full Text] [Related]
7. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Immunotherapy and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yu S; Zhai S; Gong Q; Xiang C; Gong J; Wu L; Pu X
Am J Clin Oncol; 2023 Nov; 46(11):517-528. PubMed ID: 37749786
[TBL] [Abstract][Full Text] [Related]
9. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
Liu W; Zhang T; Zhang Q; Li L; Xu C
BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
Wang J; Tong T; Zhang G; Jin C; Guo H; Liu X; Zhang Z; Li J; Zhao Y
Front Immunol; 2024; 15():1339757. PubMed ID: 38352873
[TBL] [Abstract][Full Text] [Related]
12. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Zhang C; Hong HZ; Wu YL; Zhong WZ
JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis.
Xu H; Li T; Shao G; Wang W; He Z; Xu J; Qian Y; Liu H; Ge H; Wang L; Zhang D; Yang L; Li F; Xu Z
Front Immunol; 2023; 14():1193614. PubMed ID: 37426646
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis.
Wang H; Liu T; Chen J; Dang J
Front Oncol; 2022; 12():901494. PubMed ID: 36212419
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis.
Ge S; Huang C
J Thorac Dis; 2022 Feb; 14(2):333-342. PubMed ID: 35280480
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis.
Huang S; Huang Y; Li C; Liang Y; Huang M; Luo R; Liang W
Front Immunol; 2023; 14():1332213. PubMed ID: 38264649
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Jiang J; Wang Y; Gao Y; Sugimura H; Minervini F; Uchino J; Halmos B; Yendamuri S; Velotta JB; Li M
Transl Lung Cancer Res; 2022 Feb; 11(2):277-294. PubMed ID: 35280319
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.
Alifu M; Tao M; Chen X; Chen J; Tang K; Tang Y
Front Oncol; 2023; 13():1146905. PubMed ID: 37397392
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
